Waters C H
Department of Neurology, University of Southern California, Los Angeles 90033.
Can J Neurol Sci. 1994 Aug;21(3):259-61. doi: 10.1017/s031716710004124x.
The use of the combination of fluoxetine, an anti-depressant serotonin uptake inhibitor, and selegiline, a monoamine oxidase -B inhibitor, was reviewed in a large population of patients with Parkinson's disease. All records were reviewed from a Parkinson's disease clinic to determine how many patients were treated simultaneously with selegiline and fluoxetine. Patient characteristics, duration and dose of treatment, side effects and reasons for discontinuation were noted. Twenty-three patients received both medications at the same time. No additional side effects were noted with the combination therapy that had not already been reported with each medication alone. No serious side effects were found. In this clinic population, fluoxetine and selegiline were used in combination without major side effects, but further observation is warranted.
在一大群帕金森病患者中，对使用抗抑郁血清素摄取抑制剂氟西汀和单胺氧化酶 -B 抑制剂司来吉兰的联合用药情况进行了回顾。查阅了一家帕金森病诊所的所有记录，以确定同时接受司来吉兰和氟西汀治疗的患者数量。记录了患者特征、治疗持续时间和剂量、副作用以及停药原因。23 名患者同时接受了这两种药物治疗。联合治疗未发现单独使用每种药物时未报告过的额外副作用。未发现严重副作用。在该诊所的患者群体中，氟西汀和司来吉兰联合使用未出现重大副作用，但仍需进一步观察。
